Adimanebart (ARGX-119) is a novel anti-MuSK (muscle-specific kinase) agonist monoclonal antibody being developed as a pipeline in a product for neuromuscular diseases. argenx is seeking a dynamic clinical development leader to provide expertise across multiple indications, including CMS (congenital myasthenic syndromes), ALS (amyotrophic lateral sclerosis), and SMA (spinal muscular atrophy) clinical programs, while also driving the rapid evaluation of new indications. The candidate will be responsible for delivering strategic clinical development leadership and oversight as part of the Asset Strategy Team (a cross-functional group focused on maximizing asset potential), working closely with other team members and the indication development teams to maximize the value of the asset and the success of the multi-indication program. The ideal candidate will have significant experience in clinical development for neurologic disorders and a proven track record in drug development.
Deliver strategic clinical development planning and insight for the asset across all stages, including TPP, indication selection, labelling, and assessment of efficacy, safety, and competitor data. Oversee and guide the clinical development physicians, setting standards, coaching, and identifying high performers. Enhance external client satisfaction through strong collaboration with academic medical centers, positioning argenx as a partner of choice and ensuring valuable scientific input. Support internal clients by closely working with senior management and function heads, anticipating needs and ensuring clinical development excellence. Foster cross-functional collaboration on policies and training to streamline procedures and improve efficiency; ensure quality clinical development partnerships. Build and sustain a top-tier clinical development physician team.